Viking Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $345.0M | $101.6M | $63.8M | $54.2M | $45.0M | $31.9M | $23.6M | $19.0M |
| SG&A Expense | $48.4M | $49.3M | $37.0M | $16.1M | $10.7M | $10.7M | $9.1M | $7.1M |
| Operating Income | $-393.3M | $-150.9M | $-100.8M | $-70.4M | $-55.7M | $-42.7M | $-32.7M | $-26.2M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-359.6M | $-110.0M | $-85.9M | — | — | — | — | — |
| Income Tax Expense | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $0 | $0 | $0 |
| Net Income | $-359.6M | $-110.0M | $-85.9M | $-68.9M | $-55.0M | $-39.5M | $-25.8M | $-22.1M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-3.19 | $-1.01 | $-0.91 | $-0.90 | $-0.71 | $-0.54 | $-0.36 | $-0.38 |
| EPS (Diluted) | $-3.19 | $-1.01 | $-0.91 | $-0.90 | $-0.71 | $-0.54 | $-0.36 | $-0.38 |
| Shares Outstanding (Basic) | 112.7M | 109.0M | 94.3M | 76.8M | 77.2M | 73.2M | 72.4M | 71.7M |
| Shares Outstanding (Diluted) | 112.7M | 109.0M | 94.3M | 76.8M | 77.2M | 73.2M | 72.4M | 71.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |